To achieve this we combine: 1) radiation to enhance tumor cell immunogenicity, 2) the tumor-specific mAb, cetuximab, to enhance tumor destruction and antigen presentation by immune cells that express Fc-γ receptor (FcγR) including NK cells and macrophages, and 3) anti–PD-L1 immune checkpoint inhibition to augment and propagate an adaptive anti-tumor immune response. Here, FCGR2A is linked to neoplasm.